SIGA Technologies, Inc.
Moat Score — SIGA Technologies, Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | SIGA holds the only FDA-approved oral antiviral specifically for smallpox (TPOXX), with additional approvals in the EU, Canada, UK, and as of December 2024 Japan — a regulatory and clinical-data moat built over many years that a new entrant could not quickly replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | SIGA owns no manufacturing facilities and relies entirely on contract manufacturers for TPOXX production, so it has no structural cost advantage over a hypothetical competitor — its profitability comes from regulatory exclusivity, not production efficiency. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As effectively the sole supplier of an FDA-approved oral smallpox antiviral to the U.S. Strategic National Stockpile and international governments, SIGA negotiates large procurement contracts (the BARDA 19C contract alone up to ~$602.5 million) without a directly substitutable competing product. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | SIGA's business is a government-procurement pharmaceutical model with no network effect — value does not increase as more governments or patients use TPOXX in the way a platform or marketplace would compound. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once TPOXX is qualified into a national stockpile's formulary and emergency-use protocols, re-qualifying an alternative antiviral would require new regulatory review and government budget approval, giving some inertia — but stockpile contracts are periodically rebid and BARDA options are exercised at the government's sole discretion. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The biodefense antiviral niche is small enough that only SIGA and a handful of players like Emergent BioSolutions and Bavarian Nordic (a vaccine, not antiviral, competitor) meaningfully participate, limiting new entry, though the market's small absolute size is itself a risk rather than purely a moat. |